Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

259.24 +2.26 (+0.88%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now? ↗
They are going through a rough patch, but it's too early to give up on them. 
Via The Motley Fool
Topics World Trade
News headline image
Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech ↗
Intuitive Surgical is a leader in the surgical robotics space, with a large installed base and strong recurring revenues. 
Via The Motley Fool
News headline image
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗
XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Solventum Nears Inflection Point As It Begins to Unlock Value ↗
Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers. 
Via MarketBeat
Topics Initial Public Offering
News headline image
Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night. ↗
These healthcare giants can deliver steady gains. 
Via The Motley Fool
News headline image
The Market Is Flashing a Valuation Warning -- but History Shows These Stocks Can Handle the Turbulence ↗
Investors may want to brace for turbulence. But these stocks should hold up well. 
Via The Motley Fool
Topics Economy
What's going on in today's session: dow jones movers ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Issued on behalf of Helus Pharma (Nasdaq: HELP) 
From USA News Group
Via GlobeNewswire
News headline image
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
From Johnson & Johnson
Via Business Wire
Which dow jones stocks are moving on Tuesday? ↗
Via Chartmill
Tuesday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU) 
From American News Group
Via GlobeNewswire
News headline image
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
From Johnson & Johnson
Via Business Wire
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
Top dow jones movers in Monday's session ↗
Via Chartmill
News headline image
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure ↗
As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV). 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
News headline image
Johnson & Johnson’s OTTAVA Robotic Surgery System Targets Long-Term Growth ↗
Johnson & Johnson (NYSE:JNJ) outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the... 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
3 Dividend Stocks That Are No-Brainer Buys for the Second Half of 2026 ↗
As stocks pull back from recent highs, lean into these three blue chip dividend stocks. 
Via The Motley Fool
News headline image
3 Dividend Stocks to Buy and Hold Forever ↗
They have a combined 181 years of consecutive payout increases. 
Via The Motley Fool
Topics Intellectual Property Lawsuit
News headline image
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement. 
Via The Motley Fool
These dow jones stocks are moving in today's session ↗
Via Chartmill
News headline image
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline ↗
Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves. 
Via Benzinga
News headline image
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About ↗
Things are going well for the pharmaceutical giant. 
Via The Motley Fool
Topics Lawsuit
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
Which dow jones stocks are moving on Thursday? ↗
Via Chartmill
News headline image
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals ↗
Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines. 
Via Benzinga
News headline image
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
From Johnson & Johnson
Via Business Wire
News headline image
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗
But is that performance sustainable? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.